CD274 and non-small cell lung carcinoma: In particular, anti-programmed death-1 (PD-1) or anti-programmed death ligand-1 (PD-L1) antibodies such as nivolumab, pembrolizumab, and atezolizumab show significant efficacy in patients with advanced non-small cell lung cancer (NSCLC).